Pipeline

Internally Sponsored Programs

Enteris BioPharma’s internal pipeline of products are being evaluated in the clinic and include Ovarest® and Tobrate.

Enteris BioPharma is enhancing the value of its Peptelligence® oral drug delivery platform by developing an innovative internal clinical pipeline of orally delivered therapeutics that have been previously marketed as injectable-only formulations. Enteris has developed a strong regulatory strategy involving the use of the 505(b)(2) regulatory pathway, allowing the company to take advantage of existing safety data.

Find out how to partner with Enteris BioPharma’s internal clinical programs

Externally Sponsored Programs

Enteris BioPharma’s oral peptide and small molecule delivery technology has been applied to a range of molecules across multiple therapeutic areas.

The technology is the subject of several active externally sponsored pre-clinical and clinical development programs, the most advanced of which include R-Pharm’s TBRIA, an oral calcitonin for patients with postmenopausal osteoporosis, and an oral formulation of Cara Therapeutics’ KORSUVA, a potent peripheral kappa opioid receptor agonist with a primary focus for the treatment of pruritus.

Find out how to leverage Enteris BioPharma’s formulation expertise for your peptide or small molecule

CANDIDATE
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
TREATMENT
ENTERIS BIOPHARMA
Ovarest®
(0ral Leuprolide Tablet)
  • 62%
Multiple Treatments
Tobrate™
(Oral Tobramycin Tablet)
  • 37%
uUTI
Oral Octreotide Tablet
  • 20%
NET Assoc. Disorders
CARA THERAPEUTICS
KORSUVA™
(oral CR845)
  • 80%
Pruritus CKD (III-IV)
KORSUVA™
(oral CR845)
  • 62%
Pruritus CLD
KORSUVA™
(oral CR845)
  • 62%
Pruritus Atopic Dermatitis
NORDIC BIOSCIENCE
DACRA Peptides
  • 25%
Metabolic Disorder
OTHER PROGRAMS
Oral Calcitonin
  • 90%
Osteoporosis
GnRH Analogs
  • 25%
Various
GLP-1 Analogs
  • 25%
Type 2 Diabetes
Peptide & Small Molecules
  • 25%
Various